June 24, 2014

CD19 Inhibitor Shows Promise in Non-Hodgkin Lymphoma

A novel inhibitor of CD19 was well tolerated and showed promising activity in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL), according to a phase I study.

UAB in the News

 
 
Back to Top